Bank of America Corp DE Sells 27,649 Shares of Agios Pharmaceuticals Inc (AGIO)

Bank of America Corp DE decreased its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 46.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,345 shares of the biopharmaceutical company’s stock after selling 27,649 shares during the quarter. Bank of America Corp DE’s holdings in Agios Pharmaceuticals were worth $2,640,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Tiverton Asset Management LLC acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $142,000. NewSquare Capital LLC acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $182,000. Strs Ohio acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $179,000. Barrett Asset Management LLC acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $253,000. Finally, Creative Planning acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $394,000. Hedge funds and other institutional investors own 94.38% of the company’s stock.

NASDAQ AGIO opened at $71.34 on Wednesday. Agios Pharmaceuticals Inc has a twelve month low of $51.62 and a twelve month high of $99.82. The company has a market cap of $4.09 billion, a price-to-earnings ratio of -10.57 and a beta of 2.04.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative return on equity of 48.51% and a negative net margin of 461.78%. The firm had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $22.72 million. During the same quarter in the previous year, the firm posted ($1.59) earnings per share. The company’s revenue for the quarter was up 33.8% on a year-over-year basis. As a group, equities analysts anticipate that Agios Pharmaceuticals Inc will post -6.2 earnings per share for the current year.

In other news, Director John Maraganore sold 13,555 shares of the business’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total transaction of $986,126.25. Following the transaction, the director now directly owns 38,609 shares in the company, valued at approximately $2,808,804.75. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Christopher Bowden sold 1,700 shares of the business’s stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $80.03, for a total transaction of $136,051.00. Following the transaction, the insider now owns 1,224 shares in the company, valued at $97,956.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,305 shares of company stock worth $1,734,343. Corporate insiders own 3.02% of the company’s stock.

Several research analysts have issued reports on AGIO shares. Cann restated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. BidaskClub upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. Guggenheim began coverage on shares of Agios Pharmaceuticals in a research report on Monday, September 17th. They set a “neutral” rating on the stock. ValuEngine cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 11th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $96.27.

ILLEGAL ACTIVITY WARNING: “Bank of America Corp DE Sells 27,649 Shares of Agios Pharmaceuticals Inc (AGIO)” was originally published by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://theenterpriseleader.com/2018/11/07/bank-of-america-corp-de-sells-27649-shares-of-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Article: What is a balanced fund?

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply